Mini-review on the properties and possible applications of therapeutic oxygen carrier Hemarina-M101

Varney, Joseph; Rivera, Amanda; Dong, Vinh; Tieu, Thuan Minh; Zia, Sairah; Huy, Nguyen Tien

doi:10.1016/j.transci.2020.103016

Cited by 8 publications

(12 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…HemO 2 Life/Hemarina-M101 (Hemarina) was created from lungworms, Arenicola marina (invertebrate), which is not attached to Hb or other membranes (Ferenz and Steinbicker 2019 ; Bedőcs and Szebeni 2020 ; Varney et al 2021 ). Hb (extracellular) has 40 times more oxygen receptivity than vertebrate Hb (Lupon et al 2021 ).…”

Section: Aocs and Their Benefitsmentioning

confidence: 99%

“…In 2020, HemO 2 Life/ Hemarina-M101 was used for oxygen therapy in life-threatening COVID-19 patients with severe respiratory problems; it is currently an ongoing study (Lupon et al 2021 ). HemO 2 Life completed phase I study in 2018; phases II and III (NCT04181710) are currently in progress to determine its efficacy in renal transplantation (Lupon et al 2021 ) because of its high oxygen carrying capability with minimal side effects (Bedőcs and Szebeni 2020 ; Varney et al 2021 , p. 101). The clinical trials of chemically altered HBOCs are summarized in Table 3 .…”

Section: Aocs and Their Benefitsmentioning

confidence: 99%

See 1 more Smart Citation

Current perspectives of artificial oxygen carriers as red blood cell substitutes: a review of old to cutting-edge technologies using in vitro and in vivo assessments

Mohanto

Park

Jee

2022

J. Pharm. Investig.

View full text Add to dashboard Cite

Section: Aocs and Their Benefitsmentioning

confidence: 99%

Section: Aocs and Their Benefitsmentioning

confidence: 99%

Current perspectives of artificial oxygen carriers as red blood cell substitutes: a review of old to cutting-edge technologies using in vitro and in vivo assessments

Mohanto

Park

Jee

2022

J. Pharm. Investig.

View full text Add to dashboard Cite

“…17 It releases O 2 according to the partial pressure of O 2 at the site and demonstrated interesting anti-inflammatory, antibacterial, and superoxide dismutase (SOD) like properties 15,18,19 allowing its use as an organ preservative. 20,21 In the context of periodontal tissues, it was observed that M101 was not cytotoxic for gingival epithelial cells and fibroblasts in its liquid form or within hyaluronic acid based hydrogel. 15,18 Moreover, M101 was able to decrease P. gingivalis growth and P. gingivalis elicited inflammatory response in oral epithelial cells notably TNF-α secretion.…”

Section: Introductionmentioning

confidence: 99%

“…M101 can carry 156 molecules of O 2 corresponding to 40 times the number of O 2 transported by human hemoglobin 17 . It releases O 2 according to the partial pressure of O 2 at the site and demonstrated interesting anti‐inflammatory, antibacterial, and superoxide dismutase (SOD) like properties 15,18,19 allowing its use as an organ preservative 20,21 . In the context of periodontal tissues, it was observed that M101 was not cytotoxic for gingival epithelial cells and fibroblasts in its liquid form or within hyaluronic acid based hydrogel 15,18 .…”

Section: Introductionmentioning

confidence: 99%

M101, a therapeutic oxygen carrier derived fromArenicola marina, decreasedPorphyromonas gingivalis‐induced hypoxia and improved periodontal healing

Batool

Petit

Stutz

et al. 2022

Journal of Periodontology

View full text Add to dashboard Cite

Background Porphyromonas gingivalis exacerbates tissue hypoxia and worsens periodontal inflammation. This study investigated the effect of a therapeutic oxygen carrier (M101), derived from Arenicola marina, on hypoxia and associated inflammation in the context of periodontitis. Methods The effect of M101 on GLUT‐1, GLUT‐3, HIF‐1α, and MMP‐9 expression, hypoxia, and antioxidant status in oral epithelial cells (EC) exposed to CoCl2 (1000 μM), P. gingivalis (MOI 100), and CoCl2 + P. gingivalis was evaluated through hypoxia detection fluorescence assay, antioxidant concentration colorimetric assay, and RTqPCR. Evaluation of M101 on EC proliferation was evaluated in an in vitro wound assay. In experimental periodontitis, periodontal wound healing and osteoclastic activity were compared among natural wound healing, placebo, and gels containing M101 (1 and 2 g/L) groups through histomorphometry and TRAP (tartrate‐resistant acid phosphatase activity assay) assay respectively. The expression of HIF‐1α, MMP‐9, and NFκB in periodontal tissues was also evaluated through immunofluorescence studies. Results M101 downregulated GLUT‐1, GLUT‐3, HIF‐1α, and MMP‐9 levels in EC exposed to CoCl2, P. gingivalis, and CoCl2 + P. gingivalis (p < 0.05). Fluorescence and colorimetric analyses confirmed hypoxia reduction and antioxidant capacity improvement in such EC upon M101 treatment. Moreover, M101 improved significantly the in vitro wound closure. In vivo, the attachment level was significantly improved, and osteoclastic activity was reduced in mice treated with M101 gels compared to placebo and natural wound healing groups (p < 0.05). HIF‐1α, MMP‐9, and NFκB expression in periodontal tissues was reduced in M101 gels treated mice compared to the controls. Conclusion M101 showed promise in resolving hypoxia and associated inflammation‐mediated tissue degradation. Its potential in the clinical management of periodontitis must be further investigated.

show abstract

“…Arenicola marina ) ( Bhattacharjee et al, 2020 ; Bodewes et al, 2021 ). However, they require intensive purification for their use, and their passive oxygen release kinetics makes them poorly controllable depending on the organ metabolic needs ( Le Meur et al, 2020 ; Varney et al, 2021 ). As a purely synthetic alternative, perfluorocarbons have limitations due to the difficulty of controlling the kinetics of oxygen release, as well as the complexity of manufacturing and the need to incorporate them into different emulsions, limiting their widespread adoption in organ preservation ( Malchesky, 2017 ; Jägers et al, 2021 ).…”

Section: Introductionmentioning

confidence: 99%

Development of a Novel Perfusable Solution for ex vivo Preservation: Towards Photosynthetic Oxygenation for Organ Transplantation

Veloso-Giménez

Escamilla

Necuñir

et al. 2021

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Oxygen is the key molecule for aerobic metabolism, but no animal cells can produce it, creating an extreme dependency on external supply. In contrast, microalgae are photosynthetic microorganisms, therefore, they are able to produce oxygen as plant cells do. As hypoxia is one of the main issues in organ transplantation, especially during preservation, the main goal of this work was to develop the first generation of perfusable photosynthetic solutions, exploring its feasibility for ex vivo organ preservation. Here, the microalgae Chlamydomonas reinhardtii was incorporated in a standard preservation solution, and key aspects such as alterations in cell size, oxygen production and survival were studied. Osmolarity and rheological features of the photosynthetic solution were comparable to human blood. In terms of functionality, the photosynthetic solution proved to be not harmful and to provide sufficient oxygen to support the metabolic requirement of zebrafish larvae and rat kidney slices. Thereafter, isolated porcine kidneys were perfused, and microalgae reached all renal vasculature, without inducing damage. After perfusion and flushing, no signs of tissue damage were detected, and recovered microalgae survived the process. Altogether, this work proposes the use of photosynthetic microorganisms as vascular oxygen factories to generate and deliver oxygen in isolated organs, representing a novel and promising strategy for organ preservation.

show abstract

Mini-review on the properties and possible applications of therapeutic oxygen carrier Hemarina-M101

Cited by 8 publications

References 17 publications

Current perspectives of artificial oxygen carriers as red blood cell substitutes: a review of old to cutting-edge technologies using in vitro and in vivo assessments

Current perspectives of artificial oxygen carriers as red blood cell substitutes: a review of old to cutting-edge technologies using in vitro and in vivo assessments

M101, a therapeutic oxygen carrier derived fromArenicola marina, decreasedPorphyromonas gingivalis‐induced hypoxia and improved periodontal healing

Development of a Novel Perfusable Solution for ex vivo Preservation: Towards Photosynthetic Oxygenation for Organ Transplantation

Contact Info

Product

Resources

About